309 related articles for article (PubMed ID: 23190500)
61. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells.
Wagener N; Holland D; Bulkescher J; Crnković-Mertens I; Hoppe-Seyler K; Zentgraf H; Pritsch M; Buse S; Pfitzenmaier J; Haferkamp A; Hohenfellner M; Hoppe-Seyler F
Int J Cancer; 2008 Oct; 123(7):1545-50. PubMed ID: 18623083
[TBL] [Abstract][Full Text] [Related]
62. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
63. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
Poirier JT; Gardner EE; Connis N; Moreira AL; de Stanchina E; Hann CL; Rudin CM
Oncogene; 2015 Nov; 34(48):5869-78. PubMed ID: 25746006
[TBL] [Abstract][Full Text] [Related]
64. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
[TBL] [Abstract][Full Text] [Related]
65. Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.
Tegeder I; Thiel K; Erkek S; Johann PD; Berlandi J; Thatikonda V; Frühwald MC; Kool M; Jeibmann A; Hasselblatt M
J Neurooncol; 2019 Jan; 141(1):43-55. PubMed ID: 30446899
[TBL] [Abstract][Full Text] [Related]
66. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.
Li Z; Wang Y; Qiu J; Li Q; Yuan C; Zhang W; Wang D; Ye J; Jiang H; Yang J; Cheng J
Oncotarget; 2013 Dec; 4(12):2532-49. PubMed ID: 24345883
[TBL] [Abstract][Full Text] [Related]
67. Molecular array analyses of 51 pediatric tumors shows overlap between malignant intracranial ectomesenchymoma and MPNST but not medulloblastoma or atypical teratoid rhabdoid tumor.
Kleinschmidt-DeMasters BK; Lovell MA; Donson AM; Wilkinson CC; Madden JR; Addo-Yobo SO; Lillehei KO; Foreman NK
Acta Neuropathol; 2007 Jun; 113(6):695-703. PubMed ID: 17431644
[TBL] [Abstract][Full Text] [Related]
68. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
69. Dynamic changes in Ezh2 gene occupancy underlie its involvement in neural stem cell self-renewal and differentiation towards oligodendrocytes.
Sher F; Boddeke E; Olah M; Copray S
PLoS One; 2012; 7(7):e40399. PubMed ID: 22808153
[TBL] [Abstract][Full Text] [Related]
70. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
[TBL] [Abstract][Full Text] [Related]
71. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis.
Zhang P; Garnett J; Creighton CJ; Al Sannaa GA; Igram DR; Lazar A; Liu X; Liu C; Pollock RE
J Pathol; 2014 Feb; 232(3):308-18. PubMed ID: 24132643
[TBL] [Abstract][Full Text] [Related]
72. Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration.
Chun HE; Johann PD; Milne K; Zapatka M; Buellesbach A; Ishaque N; Iskar M; Erkek S; Wei L; Tessier-Cloutier B; Lever J; Titmuss E; Topham JT; Bowlby R; Chuah E; Mungall KL; Ma Y; Mungall AJ; Moore RA; Taylor MD; Gerhard DS; Jones SJM; Korshunov A; Gessler M; Kerl K; Hasselblatt M; Frühwald MC; Perlman EJ; Nelson BH; Pfister SM; Marra MA; Kool M
Cell Rep; 2019 Nov; 29(8):2338-2354.e7. PubMed ID: 31708418
[TBL] [Abstract][Full Text] [Related]
73. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.
van Vlerken LE; Kiefer CM; Morehouse C; Li Y; Groves C; Wilson SD; Yao Y; Hollingsworth RE; Hurt EM
Stem Cells Transl Med; 2013 Jan; 2(1):43-52. PubMed ID: 23283488
[TBL] [Abstract][Full Text] [Related]
74. 16-hydroxycleroda-3,13-dien-15,16-olide regulates the expression of histone-modifying enzymes PRC2 complex and induces apoptosis in CML K562 cells.
Lin YH; Lee CC; Chang FR; Chang WH; Wu YC; Chang JG
Life Sci; 2011 Dec; 89(23-24):886-95. PubMed ID: 21983300
[TBL] [Abstract][Full Text] [Related]
75. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer.
Fang J; Zhang M; Li Q
Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038
[TBL] [Abstract][Full Text] [Related]
76. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.
Tekautz TM; Fuller CE; Blaney S; Fouladi M; Broniscer A; Merchant TE; Krasin M; Dalton J; Hale G; Kun LE; Wallace D; Gilbertson RJ; Gajjar A
J Clin Oncol; 2005 Mar; 23(7):1491-9. PubMed ID: 15735125
[TBL] [Abstract][Full Text] [Related]
77. Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression.
Xu L; Deng Q; Pan Y; Peng M; Wang X; Song L; Xiao M; Wang Z
Int J Mol Med; 2014 Jan; 33(1):91-6. PubMed ID: 24212330
[TBL] [Abstract][Full Text] [Related]
78. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
79. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
80. Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities.
Paassen I; Williams J; Ríos Arceo C; Ringnalda F; Mercer KS; Buhl JL; Moreno N; Federico A; Franke NE; Kranendonk M; Upadhyaya SA; Kerl K; van de Wetering M; Clevers H; Kool M; Hoving EW; Roussel MF; Drost J
Oncogene; 2023 May; 42(20):1661-1671. PubMed ID: 37020038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
